The US Food and Drug Administration approved CSPC Pharmaceutical's (HKG:1093) clinical trials for its SYH2051 for advanced solid tumors, according to a Thursday filing with the Hong Kong exchange.
The drug is an ataxia telangiectasia mutated or ATM inhibitor, which delays the repair of DNA double-strand breaks in tumor cells, the filing said.
SYH2051 showed good selectivity of ATM targets, according to the filing.
The drug also obtained China approval for clinical trials in June 2023.
Shares rose 2% during Friday's afternoon trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.